Chinese Hawthorn for Health & Longevity - Quick Reference Sheet
evipedia.ai ← Back

Chinese Hawthorn for Health & Longevity

Created on 08/21/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5 – Audit

Trials of European relatives show better exercise tolerance and fewer symptoms in mild heart failure, but no fewer heart attacks or deaths. Blood pressure falls modestly, though trials disagree, and blood fats improve. For the Chinese species alone, claims rest on animals and cells. Harms are mild; the real hazards are replacing proven treatment or buying a mislabeled product. (Full Review)

Protocol

Standardized extract, European model
900–1,800 mg daily
Leaf-and-flower dry extract standardized to 18.75% oligomeric procyanidins
Whole-fruit, Chinese model
9–12 g daily
Dried Crataegus pinnatifida fruit as decoction, stir-fried slices, or granules
Time of day
With or just after the two largest meals
Split: every positive trial used two or three daily doses
Time to effect
Heart-failure symptoms
8 weeks or later
When symptom and exercise-capacity trials measured change
Blood lipids
8 to 16 weeks
Triglycerides fell over 12 weeks
Blood pressure
8 to 16 weeks
Nothing supports judging hawthorn before 8 weeks of consistent dosing

Benefits

Contraindications
  • Pregnancy and breastfeeding, at any dose
  • New York Heart Association Class IV or any decompensated heart failure
  • Symptomatic bradycardia, sick sinus syndrome, or second- or third-degree heart block without a pacemaker
  • Resting heart rate below 50 beats per minute
  • Resting systolic blood pressure below 100 mmHg, or documented orthostatic hypotension with falls
  • Within 90 days of a myocardial infarction or any cardiac device implantation
  • Known gastroparesis, prior gastric bezoar, or active peptic ulcer disease (raw or dried whole fruit, not standardized extracts)
  • Documented rose-family food allergy (apple, pear, peach, almond) with systemic reactions
  • Camphor-containing circulatory drops (over-the-counter), for anyone taking hawthorn to lower blood pressure
Key Interactions
  • Digoxin (prescription)
  • Beta-blockers, calcium channel blockers, angiotensin-converting enzyme (ACE) inhibitors, and angiotensin receptor blockers (metoprolol, amlodipine, lisinopril, losartan)
  • Nitrates and other vasodilators (isosorbide mononitrate, sildenafil, and similar agents)
  • Anticoagulants and antiplatelets (warfarin, apixaban, clopidogrel)
  • Decongestants (pseudoephedrine, phenylephrine)
  • Antacids and acid-suppressing agents (proton-pump inhibitors, calcium carbonate)
  • Blood-pressure-lowering supplements (garlic, hibiscus, beetroot nitrate, magnesium, potassium, coenzyme Q10, arginine)
  • Lipid-lowering supplements (berberine, red yeast rice, plant sterols, soluble fiber)
  • Other interventions (time-restricted eating, aggressive carbohydrate restriction, sauna use)

Risk & Side Effects

  • High: Dizziness and vertigo; gastrointestinal complaints
    •
  • Medium: Palpitations; headache and migraine; additive blood-pressure lowering with antihypertensive drugs; no reduction in cardiac events, with displacement risk
  • Low: Gastric phytobezoar from concentrated raw fruit; skin hypersensitivity; adulterated or misidentified products
  • Speculative: Uterine stimulation in pregnancy; additive cardiac-glycoside effect with digoxin; blood-sugar lowering alongside diabetes medication

Monitoring

Marker Target Why
Home blood pressure (seated average) Below 120/75 mmHg Primary responsive target and the main additive-risk site
Resting heart rate 50–70 beats per minute Detects excessive slowing when combined with beta-blockers or digoxin
Triglycerides Below 100 mg/dL The lipid that moved most in hawthorn trials
Total cholesterol 150–200 mg/dL Fell in the pooled hawthorn-formula trials
Low-density lipoprotein cholesterol Below 100 mg/dL, below 70 with established plaque Improved less on hawthorn than on standard drugs, so it defines the ceiling
High-density lipoprotein cholesterol Above 50 mg/dL (women), above 45 mg/dL (men) Rose in the pooled hawthorn analysis
Apolipoprotein B Below 80 mg/dL Counts artery-entering particles, a better risk marker than low-density lipoprotein cholesterol alone
Fasting glucose 75–90 mg/dL Improved in hawthorn fatty-liver arms; guards additive lowering with diabetes drugs
Glycated hemoglobin Below 5.4% Confirms whether any glucose change is real or a single-day artifact
Alanine aminotransferase Below 20 U/L (men), below 17 U/L (women) Tracks the liver-fat endpoint and screens for herb-induced liver injury
High-sensitivity C-reactive protein Below 0.5 mg/L Tests the antioxidant and anti-inflammatory claim made for the polyphenols
N-terminal pro-B-type natriuretic peptide Below 125 pg/mL Objective measure of cardiac strain where a heart indication exists
Serum digoxin (only if co-prescribed) 0.5–0.9 ng/mL Detects any additive cardiac-glycoside effect

Cadence: Baseline before starting, while nothing else is changing; home blood pressure and resting pulse weekly throughout; full panel again at 12 weeks and, if continuing, every 6 to 12 months. Serum digoxin rechecked 4 weeks after starting or stopping.

Qualitative Assessment

  • Fullness, bloating, or heaviness in the two hours after a fatty or protein-heavy meal
  • Breathlessness and perceived effort at a fixed exercise workload, rated the same way each week
  • Awareness of the heartbeat at rest, and any new fluttering or skipped-beat sensation
  • Light-headedness on standing quickly, especially in the first two weeks and after any dose increase
  • Daytime energy and post-meal alertness, scored simply and consistently rather than precisely
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.